GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (FRA:OCD1) » Definitions » Notes Receivable

ChromaDex (FRA:OCD1) Notes Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ChromaDex Notes Receivable?

ChromaDex's Notes Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


ChromaDex Notes Receivable Historical Data

The historical data trend for ChromaDex's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Notes Receivable Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ChromaDex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ChromaDex Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


ChromaDex Notes Receivable Related Terms

Thank you for viewing the detailed overview of ChromaDex's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (FRA:OCD1) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.

ChromaDex (FRA:OCD1) Headlines

No Headlines